Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity. 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months.

    Helena Yu, MD, reported a financial interest/relationship or affiliation in the form of Research funding to institution: AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Janssen Oncology, Black Diamond, Blueprint Medicines, Pfizer, Inc., Systimmune, Novartis Pharmaceuticals Corporation, Cullinan & Taiho Pharmaceutical Co., Ltd. Consulting: AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Janssen Oncology, Cullinan, Taiho Pharmaceutical Co., Ltd., Takeda Oncology & Amgen, Inc.

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Wilma Guerra, BELS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the role of HER3 biology and the rationale for HER3-directed ADCs in the management of EGFRm NSCLC, including overcoming resistance mechanisms.
    • Integrate emerging evidence for HER3-directed ADCs in the team-based management of advanced EGFRm NSCLC following progression on EGFR-targeted therapies.
    • Develop best practice strategies in the multidisciplinary team-based surveillance and management of treatment-related adverse events.
    • Apply SDM when considering individualized treatment plans with patients/caregivers to optimize therapeutic selection and improve patient outcomes when using HER3-directed ADCs.
  • Target Audience

    This educational activity is designed for community-based U.S. oncologists, oncology advanced practice clinicians, pulmonologists, oncology nurses, nurse navigators, clinical and board-certified oncology pharmacists, and other members of the multidisciplinary care team responsible for the therapeutic management of patients with EGFRm NSCLC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until 9/13/2025. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-24-064-H01-P.

     Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)


    AXIS Medical Education enhances the knowledge, skills/strategy, and performance of the interprofessional healthcare team to ensure patients receive quality care, resulting in improved patient outcomes. We engage the interprofessional healthcare team in fair-balanced, scientifically rigorous, expert-led educational activities designed to foster lifelong learning that is applicable to clinical practice and patient-centered care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.

  • AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at info@axismeded.com

    There is no fee for this educational activity.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    The treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC) that has progressed on EGFR TKI therapy remains a clinical challenge, as traditional therapies have yielded only modest results. However, recent findings show that targeting HER3 can produce dramatically improved clinical outcomes. Data are rapidly emerging from late-phase trials evaluating HER3-directed antibody-drug conjugate therapies, and it is thus crucial for community-based oncologists and interprofessional care team members to be aware of these findings so they can be prepared to integrate these therapies into practice once they are available. In this activity, expert faculty in the field of NSCLC will evaluate recent data supporting the use of HER3-directed ADCs in the treatment of locally advanced and metastatic EGFR-mutated NSCLC that has progressed on EGFR TKI therapy, optimal management strategies for treatment-emergent adverse events related to these therapies, and the potential role of these agents in the current treatment paradigm. Faculty will also discuss best practices for a successful multidisciplinary approach and for optimized shared decision-making with the patient. Finally, case discussions will conclude the program to reinforce key learnings from the didactic section of the activity. 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months.

    Helena Yu, MD, reported a financial interest/relationship or affiliation in the form of Research funding to institution: AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Janssen Oncology, Black Diamond, Blueprint Medicines, Pfizer, Inc., Systimmune, Novartis Pharmaceuticals Corporation, Cullinan & Taiho Pharmaceutical Co., Ltd. Consulting: AstraZeneca Pharmaceuticals LP, Daiichi-Sankyo, Inc., Janssen Oncology, Cullinan, Taiho Pharmaceutical Co., Ltd., Takeda Oncology & Amgen, Inc.

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Wilma Guerra, BELS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the role of HER3 biology and the rationale for HER3-directed ADCs in the management of EGFRm NSCLC, including overcoming resistance mechanisms.
    • Integrate emerging evidence for HER3-directed ADCs in the team-based management of advanced EGFRm NSCLC following progression on EGFR-targeted therapies.
    • Develop best practice strategies in the multidisciplinary team-based surveillance and management of treatment-related adverse events.
    • Apply SDM when considering individualized treatment plans with patients/caregivers to optimize therapeutic selection and improve patient outcomes when using HER3-directed ADCs.
  • Target Audience

    This educational activity is designed for community-based U.S. oncologists, oncology advanced practice clinicians, pulmonologists, oncology nurses, nurse navigators, clinical and board-certified oncology pharmacists, and other members of the multidisciplinary care team responsible for the therapeutic management of patients with EGFRm NSCLC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits.  Approval is valid until 9/13/2025. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This application-based activity is approved for 0.5 contact hour of continuing pharmacy education JA4008106-0000-24-064-H01-P.

     Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

  • Provider(s)/Educational Partner(s)


    AXIS Medical Education enhances the knowledge, skills/strategy, and performance of the interprofessional healthcare team to ensure patients receive quality care, resulting in improved patient outcomes. We engage the interprofessional healthcare team in fair-balanced, scientifically rigorous, expert-led educational activities designed to foster lifelong learning that is applicable to clinical practice and patient-centered care. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.

  • AXIS Contact Information

    For information about the certification of this activity, please contact AXIS at info@axismeded.com

    There is no fee for this educational activity.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule14 Oct 2024